Orthocell's (ASX:OCC) recently secured FDA clearance for its nerve repair product, Remplir marked a "major milestone" and "de-risking event" for the company, said Euroz Hartley in a Monday note.
The company received regulatory clearance from the US Food and Drug Administration for the product, under the 510(k) pathway, allowing sales in the US market, according to a Friday filing with the Australian bourse.
The research firm noted that the approval enables Remplir to access the $1.6 billion US nerve repair market.
Euroz Hartleys raised its price target from AU$0.97 to AU$1.19 while maintaining a hold rating.
The company's shares fell 4% on market close.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。